New England Journal of Medicine Publishes Positive LTG-001 Clinical Trial Results for Acute Pain

Latigo Biotherapeutics announced the publication of positive results in the New England Journal of Medicine (NEJM) from a clinical trial evaluating LTG-001. This investigational selective Naᵥ1.8 inhibitor demonstrated rapid, clinically meaningful pain relief, favorable tolerability, and opioid-sparing potential in adults experiencing moderate-to-severe acute postoperative pain following abdominoplasty.